Ibudilast CAS 50847-11-5

Product Description:

Product Name: Ibudilast CAS NO: 50847-11-5

Synonyms:

3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine;

1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one;

2-isopropyl-3-isobutyrylpyrazolo[1,5-a]pyridine;

Chemical & Physical Properties:

Appearance: White solid

Assay :≥99.0%

Density: 1.09

Melting Point: 53-54℃

Refractive Index: 1.57

Storage Condition: 2-8℃

Safety Information:

RTECS: UR0711200

Safety Statements: S26-S36

HS Code: 2933990090

WGK Germany: 3

Risk Statements: R22; R36/37/38

Hazard Code: Xn

A leukotriene D4 antagonist. Used as an antiallergic, antiasthmatic, and vasodilator (cerebral).

Ibudilast(KC-404;AV-411;MN-166) is a relatively nonselective phosphodiesterase inhibitor which has been marketed for treating asthma.Target: PDEIbudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). The inhibition of platelet aggregation and vasodilatation by ibudilast may be due to synergistic elevation of intracellular cyclic nucleotides and release of nitric oxide (NO) or prostacyclin from endothelium, rather than direct inhibition of PDE5 or PDE3. Another important property of ibudilast is its antiinflammatory activity possibly associated with potent inhibition of PDE4. Combined with its relaxing effects on bronchial smooth muscle, antiinflammatory actvity of ibudilast could favorably influence pathophysiology of asthma by antagonizing chemical mediators triggering asthmatic attacks. Ibudilast (AV-411) is a non-selective phosphodiesterase inhibitor that is also known to suppress glial cell activation. Preclinical data indicate that ibudilast crosses the blood-brain barrier, is well tolerated, is active on oral administration, reduces glial activation and attenuates pain symptoms in diverse rat models of neuropathic pain. In addition, it enhances acute mor-phine analgesia and attenuates mor-phine tolerance and withdrawal. Thus ibudilast may improve opioid efficacy and is a promising therapeutic candidate for neuropathic pain, with a novel mechanism of action.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.